Get the Stockscreener App
246.80
1.57%
-3.93
Insulet Corporation stock is traded at $246.80, with a volume of 623.47K.
It is down -1.57% in the last 24 hours and down -5.67% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$250.73
Open:
$245
24h Volume:
623.47K
Relative Volume:
0.82
Market Cap:
$17.94B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
42.26
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
-1.86%
1M Performance:
-5.67%
6M Performance:
+7.71%
1Y Performance:
+48.44%
1-Day Range:
$234.22
$248.96
1-Week Range:
$234.22
$258.00
52-Week Range:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
246.80 | 17.94B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Study Data Show Significant Glycemic Improvements With Omnipod 5 - Medical Product Outsourcing
RBC Cuts Price Target on Insulet to $325 From $340, Keeps Outperform Rating - marketscreener.com
What's Driving the Market Sentiment Around Insulet? - Benzinga
Insulet Announces Proposal for Upcoming Financing Deals - The Healthcare Technology Report.
Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insider Sell: Insulet - marketscreener.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? - Nasdaq
Insulet's Market Expansion: The Omnipod Impact on Diabetes Care - marketscreener.com
Insulet's $389 Million Trading Day Lands 450th in Market Rankings - AInvest
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ - Medical Design & Outsourcing
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - MSN
MedTechVets Announces Veteran Placement Partnership with Insulet - WebWire
GE Vernova, Insulet lead modest stock rebound amid tariff volatility - The Business Journals
Automated Insulin Delivery Systems - Trend Hunter
Insulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7% - Yahoo Finance
Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above - The Malaysian Reserve
Citigroup Adjusts Insulet Price Target to $315 From $355, Maintains Buy Rating - marketscreener.com
Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet? - simplywall.st
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Insulin Tech Leader Insulet Readies Q1 2025 Results: What's Next for Omnipod Maker? - Stock Titan
(PODD) Trading Advice - news.stocktradersdaily.com
Insulet Stock: Is PODD Outperforming the Healthcare Sector? - Nasdaq
Insulet Stock: Is PODD Outperforming The Healthcare Sector? - Barchart.com
New Age Alpha Advisors LLC Buys Shares of 30,096 Insulet Co. (NASDAQ:PODD) - MarketBeat
3 Reasons Investors Love Insulet (PODD) - Yahoo Finance
Insulet director Frederick Wayne sells $501,875 in stock By Investing.com - Investing.com Canada
Insulet director Frederick Wayne sells $501,875 in stock - Investing.com
Insulet glows with RADIANT results, CGMs becoming T2D standard - BioWorld MedTech
Insulet Gains 62.9% in a Year: What's Driving the Stock? - Yahoo
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5% - Yahoo Finance
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corp issues $450 million in senior notes By Investing.com - Investing.com Canada
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus
PODD Stock Gains Following the Launch of Omnipod 5 in Australia - Yahoo Finance
Insulet Corp issues $450 million in senior notes - Investing.com India
Insulet Closes $450 Million Senior Notes Issuance - TipRanks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers - Yahoo Finance
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 - Nasdaq
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day - TradingView
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - BioSpace
Insulet's RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition - Nasdaq
Omnipod 5 improves diabetes control in clinical trial By Investing.com - Investing.com South Africa
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Lelezard
Insulet says data shows significant glycemic improvement with Omnipod 5 - Seeking Alpha
Insulet Reports Glycemic Improvements With Omnipod Automated Insulin Delivery System - Marketscreener.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):